Skip to main content
News

Pimicotinib Demonstrates Sustained Quality-of-Life Improvements in Tenosynovial Giant Cell Tumor

Edited by 

Clinical Summary: 

  • Design/Population: This health-related quality-of-life analysis of the phase 3 MANEUVER trial evaluated pimicotinib versus placebo in evaluable patients with tenosynovial giant cell tumor (TGCT), using EQ-5D-5L utility scores to assess patient-reported health status.

  • Key Outcomes: Pimicotinib demonstrated meaningful improvements in EQ-5D utility scores by week 25 that were maintained through week 49, with consistent findings across UK, Canadian, and Chinese scoring algorithms. Placebo recipients experienced smaller, nonclinically meaningful improvements through week 25.

  • Clinical Relevance: These findings support sustained health-related quality-of-life benefits with pimicotinib in patients with TGCT, highlighting improvements in patient-reported health status that complement previously demonstrated tumor responses and functional outcomes.

Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor (TGCT), with benefits maintained through week 49 across multiple regional scoring algorithms.

In this trial, 94 patients with TGCT were randomized 2:1 to receive either 50 mg of once daily pimicotinib or placebo for 24 weeks. Following the initial double-blind treatment period, eligible patients entered a 24-week open-label phase beginning at week 25, followed by an open-label extension beginning at week 49.

The current analysis included 92 patients evaluable for health-related quality-of-life, including 61 patients initially assigned to pimicotinib and 31 patients assigned to placebo.

Patient-reported health status was assessed using the EQ-5D-5L questionnaire every 4 weeks through week 37 and again at week 49. Age- and sex-adjusted mean utility scores were calculated using published scoring algorithms from the United Kingdom, Canada, and China. Utility scores ranged from 0, representing death, to 1, representing full health.

At baseline, patients with TGCT reported lower health-related quality-of-life than age- and sex-adjusted general populations across all 3 regional scoring algorithms.

Using the UK algorithm, mean baseline EQ-5D utility scores were 0.643 in the pimicotinib arm and 0.602 in the placebo arm, compared with 0.882 in the reference population. At week 25, the mean change from baseline was +0.135 with pimicotinib compared with +0.037 with placebo. Among patients initially randomized to pimicotinib, the improvement was maintained through week 49, with a mean change from baseline of +0.154.

Using the Canadian algorithm, mean baseline EQ-5D utility scores were 0.748 with pimicotinib and 0.706 with placebo, compared with a reference population range of 0.828 to 0.875. At week 25, mean changes from baseline were +0.093 with pimicotinib and +0.039 with placebo. By week 49, the mean change from baseline among patients initially receiving pimicotinib was +0.098.

Similarly, using the Chinese algorithm, baseline utility scores were 0.701 in the pimicotinib arm and 0.641 in the placebo arm, compared with 0.950 in the reference population. At week 25, mean changes from baseline were +0.138 with pimicotinib and +0.058 with placebo. Improvements among patients initially receiving pimicotinib were maintained through week 49, with a mean change from baseline of +0.157.

Across all 3 regional scoring algorithms, pimicotinib demonstrated greater improvements in patient-reported health status than placebo during the initial randomized treatment period, with sustained improvements observed among patients initially assigned to pimicotinib through week 49.

The investigators noted that improvements with placebo through week 25 were not considered clinically meaningful.

These findings suggest that prolonged treatment with pimicotinib may provide sustained improvements in patient-reported health status, complementing previously demonstrated improvements in tumor response, symptoms, and physical function.


Source: 

Razak ARA, Stacchiotti S, Gelderblom H, et al. The impact of pimicotinib on quality of life (QoL) in patients with tenosynovial giant cell tumor (TGCT): EQ-5D-5L findings from the phase 3 MANEUVER trial. Presented at the ESMO Congress. October 23–27, 2026; Madrid, Spain. Abstract 3756P. 

© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.